IP Library Granted Patent US 8,529,486
Granted Patent B2
US 8,529,486 · App. 13/359,109 · Granted Sep 10, 2013

Citrate anticoagulation system for extracorporeal blood treatments

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,529,486
App. No.
13/359,109
Granted
Sep 10, 2013
Kind
B2
Abstract

A hemofiltration system and method for pumping blood from a patient's blood stream into an access line, introducing an anticoagulant solution into the pumped blood, filtering the pumped blood and delivering it to a return line, introducing a substitution fluid into the pumped blood, introducing a calcium and magnesium solution into the blood traveling through the return line, and returning the blood back to the patient's blood stream.

Claims (28)

1. A hemofiltration method comprising:

pumping blood from a patient's blood stream into an access line;

introducing an anticoagulant solution into the blood;

filtering the blood;

delivering the blood, after filtering, to a return line;

introducing a substitution fluid into the blood;

introducing a calcium and magnesium solution into the blood traveling through the return line; and

returning the blood back to the patient's blood stream.

2. The hemofiltration method of claim 1 , wherein the substitution fluid is introduced into the access line.

3. The hemofiltration method of claim 1 , wherein the substitution fluid is introduced into the return line.

4. The hemofiltration method of claim 1 , wherein the substitution fluid is introduced into the access line and into the return line.

5. The hemofiltration method of claim 1 , further comprising monitoring the blood pressure in the access line.

6. The hemofiltration method of claim 1 , further comprising monitoring the blood pressure in the return line.

7. The hemofiltration method of claim 1 , further comprising:

exporting through a filtrate line a filtrate obtained from the filtering step; and

monitoring the pressure in the filtrate line to control the filtrate pressurization.

8. The hemofiltration method of claim 1 , further comprising:

exporting through a filtrate line a filtrate collected from the filtering step; and

detecting blood leakage into the filtrate line to control leakage of blood cells through the filter.

9. The hemofiltration method of claim 1 , further comprising:

exporting through a filtrate line a filtrate collected from the filtering step;

storing the filtrate traveling through the filtrate line in a reservoir;

weighing the filtrate stored in the reservoir; and

computing the amount of substation fluid introduced in the blood from the weighing step.

10. The hemofiltration method of claim 1 , further comprising:

detecting air bubbles from the blood introduced with the substation fluid; and

removing air bubbles from the blood before it is returned into the patient's blood stream.

11. The hemofiltration method of claim 1 , further comprising heating the substation fluid introduced into the blood to a temperature substantially equal to the patient's body temperature.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 10, 2014
From: BAXTER HEALTHCARE SA; BAXTER INTERNATIONAL INC.
To: NIKKISO CO., LTD.
Reel/Frame 032210/0629 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 14, 2012
From: EDWARDS LIFESCIENCES CORPORATION
To: BAXTER INTERNATIONAL INC.; BAXTER HEALTHCARE S.A.
Reel/Frame 029474/0451 →